A Study to Evaluate of the Efficacy of Enfuvirtide During the Induction Phase of Therapy
Status:
Completed
Trial end date:
2007-03-01
Target enrollment:
Participant gender:
Summary
We hypothesize that using a potent antiretroviral such as Enfuvirtide during the induction
phase of HAART therapy will lead to faster clearance of virus and infected cells, and lower
number of minority variant HIV-1 strains.
Phase:
Phase 4
Details
Lead Sponsor:
University of Maryland University of Maryland, Baltimore